key: cord-1007644-ehwyxd9h
authors: Akoglu, Gulsen
title: Pemphigus vulgaris after SARS‐CoV‐2 vaccination: A case with new‐onset and two cases with severe aggravation
date: 2022-03-15
journal: Dermatol Ther
DOI: 10.1111/dth.15396
sha: 092dfde912f38a5b324581d5b9f6d94468b0e2da
doc_id: 1007644
cord_uid: ehwyxd9h

Pemphigus may be induced or aggravated by certain drugs and vaccines. People worldwide are currently vaccinated with several SARS‐CoV‐2 vaccines which may be associated with increased number of aggravated or triggered autoimmune bullous diseases in subjects with an underlying genetic predisposition. Herein, a case of new‐onset pemphigus vulgaris (PV) and two cases with aggravation of PV after vaccinations for SARS‐CoV‐2 are reported.

vaccines is to create a potent immunological response to COVID-19.

After BNT162b2 vaccination, strong adaptive humoral and polyspecific cellular immune responses against SARS-CoV-2 are detected. 4 CoronaVac is an inactivated vaccine which is conjugated with alum for the proper stimulation of immune cells. Both vaccines produce a high level of neutralizing antibodies against SARS-CoV-2. 5 Although the antibody response after both doses of inactivated vaccine could not be measured, production of anti-dsg antibodies may likely have slowly and gradually increased. The clinical manifestations of PV may have shown up after a "silent" period due to the potentially weaker or slower T/B cell responses in older people than younger ones. 6 Although currently there is no report about the T cell responses after observations are shared to pay attention to vaccine-related new manifestations, not to diminish the importance of vaccination against the COVID-19 pandemic, which affects the whole world. Future studies are needed to enlighten the exact cause-and-effect relationship.

The author thank to Dr Elcin Kadan and Dr Egemen Akincioglu for taking pathology photographs.

The author declares no conflicts of interest. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Gulsen Akoglu https://orcid.org/0000-0002-9483-6268

The pathogenesis of bullous skin diseases

Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus

Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Influence of immune aging on vaccine responses

The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?

Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

How to cite this article: Akoglu G. Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation